Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Evolved resistance to tyrosine kinase inhibitor (TKI) targeted therapies remains a major clinical challenge. In EGFR mutant non-small cell lung cancer (NSCLC), failure of EGFR TKIs can result from both genetic and epigenetic mechanisms of acquired drug resistance. Widespread reports of histologic an...

詳細記述

保存先:
書誌詳細
出版年:Oncogene
主要な著者: Raoof, Sana, Mulford, Iain J., Frisco-Cabanos, Heidie, Nangia, Varuna, Timonina, Daria, Labrot, Emma, Hafeez, Nafeeza, Bilton, Samantha J., Drier, Yotam, Ji, Fei, Greenberg, Max, Williams, August, Kattermann, Krystina, Damon, Leah, Sovath, Sosathya, Rakiec, Daniel P., Korn, Joshua M., Ruddy, David A., Benes, Cyril H., Hammerman, Peter S., Piotrowska, Zofia, Sequist, Lecia V., Niederst, Matthew J., Barretina, Jordi, Engelman, Jeffrey A., Hata, Aaron N.
フォーマット: Artigo
言語:Inglês
出版事項: 2019
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6742540/
https://ncbi.nlm.nih.gov/pubmed/31324888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-019-0887-2
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料